7210 Wareham Drive, Tampa, FL 33647
June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the […]
Employers and Insurers Push Back on GLP-1 Drugs Coverage Read More »
March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated
U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »
January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market
Semaglutide Boom – The Beginning of a Decline? New FDA Report Read More »
Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In
Obesity Drug Sales Continue To Soar Read More »
June 5, 2023 There is no doubt that the new obesity drugs (Wegovy, Ozempic) are hot and in high demand, but there is a disturbing new trend developing. Since the brand name drugs often cost $1,000 to $1,300 per month and are not covered by insurance, people are looking for cheaper alternatives. That’s where compounding
Semaglutide Gold Rush Is On, Compounding Pharmacies Read More »
April 19, 2023 We obtained some information regarding Noom’s participation in the medical weight loss arena. “…Noom Clinical is offered to adults (18+) that are over BMI 30 or, BMI 27 and above with obesity-related conditions. Individual eligibility for specific options is determined by our trained clinicians and overseen by our Chief of Medicine. With
Noom Is Testing Weight Loss Drugs Read More »
March 20, 2023 Marketdata LLC, Tampa, FL, has just released it 17th Edition of its best-selling market research report: “The U.S. Weight Loss & Diet Control Market”. At 427 pages, with 160 Tables & Charts and 34 in-depth diet company competitor profiles, this is the most comprehensive analysis anywhere of the market. Some findings… The
Weight Loss Market Recovers to $75 Billion – New Marketdata Report Read More »